The present disclosure relates to an anticoagulant-coated microporous hollow fiber membrane showing reduced thrombogenicity. The disclosure further relates to a method for producing the membrane and a filtration and/or diffusion device comprising the membrane.

The present disclosure provides a backflow prevention device, comprising: an inlet chamber comprising at least two ports, in which a first port is used for receiving a fluid; a chamber-separating component comprising a separating member and a relief valve; an outlet chamber separated from the inlet chamber by the separating member; the relief valve being operatively connected with the separating member for opening or closing a drain port of the outlet chamber; wherein the fluid is allowed to be delivered from the outlet chamber only when the relief valve is closed by means of a differential pressure applied on the separating member. Also provided is a dialysis apparatus comprising the backflow prevention device. According to the present disclosure, the backflow prevention device has simple structure, reduced dead space and small sizes and can work reliably.

A dialysis machine (e.g., a peritoneal dialysis (PD) machine) can include a safety feature that enables the dialysis machine to automatically identify the connections made by a user in preparation for treatment. A smart connector is disclosed that uses a split RFID device that is operational when a first portion of the connector is mated to a second portion of the connector, and is not operational when the first portion is disconnected from the second portion. In an embodiment, the split RFID device incorporates an RFID chip in the first portion of the connector and an antenna in the second portion of the connector. In an embodiment, the RFID chip can store a tag that encodes information that indicates a formulation or a volume of a dialysis bag connected to the ports of a disposable cassette such that the dialysis machine can automatically discover the configuration of the dialysis setup.

The present disclosure relates to a blood treatment apparatus having of each at least one control device; one user interface; one receiving section for releasably receiving an organizer, wherein the organizer comprises components releasably connected thereto for the extracorporeal blood treatment options, in particular dialysis method being executable by the blood treatment apparatus, wherein the blood treatment apparatus comprises in particular in the area of its reception section or in the area corresponding thereto a device for the releasable fastening or fixing of the organizer (on)to the blood treatment apparatus and/or at least a device for acting on components of an organizer which is releasably received in or on the receiving section. Furthermore, an organizer is specified.

A dialysis system includes a dialysis machine comprising a motorized autoconnection mechanism, a fluid supply line connected to a source of dialysis fluid, and a cassette for use with the dialysis machine. The cassette includes a frame, a pump chamber within the frame, a first set of valves for routing the dialysis fluid from the fluid supply line to the pump chamber, and a second set of valves for routing the dialysis fluid from the pump chamber to a patient line. The cassette also includes a plurality of ports communicating with the first and second set of valves. Each port includes an integral spike. The motorized autoconnection mechanism is configured to move the fluid supply line and the patient line automatically so as to be spiked open respectively by the plurality of ports of the cassette.

Systems, methods, and devices model, identify, and predict effects of dialysis on drugs and chemical substances in patients. The systems estimate and determine effects of dialysis on elutes and drugs and solve problems with prior systems in determining effects of dialysis on drugs and dosages, especially the removal of target substances from the blood of patients during dialysis. Drug and medicine dosage adjustments for patients undergoing dialysis are made by considering the dialysis systems, patients, and drug variables and the extent to which they affect drug removal. Patients receive proper dosing by accounting for the effects of their dialysis. Systems and methods include a combination of ex vivo simulated treatments and in-silico modeling and simulation. The effects of dialysis are estimated and determined for various drugs and dosages. A reliable and effective surrogate for performing studies on patients provides guidance for use of the drugs in dialysis patients.

Hemodialysis systems are described. A hemodialysis system may include a dialysate flow path through which dialysate is passed from a dialysate reservoir, which includes a valved vent to atmosphere, to an ultrafilter. The dialysate flow path includes a pneumatically actuated diaphragm-based dialysate pump for pumping fluid from the dialysate reservoir to the ultrafilter. The hemodialysis system may include a controller for controlling pneumatic actuation pressure delivered to the dialysate pump and at least one valve connecting the dialysate reservoir vent to the atmosphere. The hemodialysis system may be configured to actuate the dialysate pump and the at least one valve to introduce air into the dialysate flow path and expel liquid from the dialysate flow path to a drain.

A medical device, such as a dialysis machine, may have multiple features and components that must be checked and attached prior to a treatment, and operators often lay tubing and other components on a surface after removing them from packaging. The system described herein provides a sterile work platform that is integrated with the medical device. In an example, the platform may be moveably coupled to the medical device. In a first position, the platform is positioned within or against the medical device, and, in a second position, the platform is extended from the medical device and disposed in a horizontal position. After the platform is extended to the second position, a surface of the platform is sterile and suitable to maintain aseptic technique for tubing and components placed on the platform. An information screen may be integrated into the platform and that provides information to an operator.

The invention relates to a method of determining a permeation property of hollow-fibre membranes wherein the permeation property of the hollow-fibre membrane is determined on a hollow-fibre membrane bundle which has been introduced into a housing and has terminally open hollow-fibre membranes at a first end of the hollow-fibre membrane bundle and terminally closed hollow-fibre membranes at a second end of the hollow-fibre membrane bundle. The invention more particularly relates to a method of determining the ultrafiltration rate and/or the ultrafiltration coefficient of hollow-fibre membranes.

The present invention provides: a porous fiber that exhibits both improved adsorption capacity, and suppressed exposure and detachment of particulates; an adsorption column filled with said porous fiber; and a blood purification system in which an adsorption column is connected to a water removal column. The porous fiber according to the present invention has a three-dimensional pore structure formed by a solid fiber, and satisfies all of the following conditions. (1) The porous fiber has particulates having a diameter of not more than 200 μm, and the percentage of area occupied by said particulates having a diameter of not more than 200 μm in a horizontal cross section of the three-dimensional pore structure is at least 3.0%. (2) The porous fiber does not contain said particulates having a diameter of not more than 200 μm in the region within 1.0 μm in the depth direction from the outermost surface.